Details
| Stereochemistry | RACEMIC |
| Molecular Formula | 2C15H13O3.Ca.2H2O |
| Molecular Weight | 558.632 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.[Ca++].CC(C([O-])=O)C1=CC=CC(OC2=CC=CC=C2)=C1.CC(C([O-])=O)C3=CC=CC(OC4=CC=CC=C4)=C3
InChI
InChIKey=LZPBLUATTGKZBH-UHFFFAOYSA-L
InChI=1S/2C15H14O3.Ca.2H2O/c2*1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13;;;/h2*2-11H,1H3,(H,16,17);;2*1H2/q;;+2;;/p-2
DescriptionSources: http://www.drugbank.ca/drugs/DB00573Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/fenoprofen.html
Sources: http://www.drugbank.ca/drugs/DB00573
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/fenoprofen.html
Fenoprofen is a propionic acid derivative with analgesic, antiinflammatory and antipyretic properties. Fenoprofen inhibits prostaglandin synthesis by decreasing the enzyme needed for biosynthesis. In patients with rheumatoid arthritis, the anti-inflammatory action of fenoprofen has been evidenced by relief of pain, increase in grip strength, and reductions in joint swelling, duration of morning stiffness, and disease activity (as assessed by both the investigator and the patient). In patients with osteoarthritis, the anti-inflammatory and analgesic effects of fenoprofen have been demonstrated by reduction in tenderness as a response to pressure and reductions in night pain, stiffness, swelling, and overall disease activity (as assessed by both the patient and the investigator). These effects have also been demonstrated by relief of pain with motion and at rest and increased range of motion in involved joints. In patients with rheumatoid arthritis and osteoarthritis, clinical studies have shown fenoprofen to be comparable to aspirin in controlling the aforementioned measures of disease activity, but mild gastrointestinal reactions (nausea, dyspepsia) and tinnitus occurred less frequently in patients treated with fenoprofen than in aspirin-treated patients. It is not known whether fenoprofen causes less peptic ulceration than does aspirin. In patients with pain, the analgesic action of fenoprofen has produced a reduction in pain intensity, an increase in pain relief, improvement in total analgesia scores, and a sustained analgesic effect. Indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Also for the relief of mild to moderate pain.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL230 Sources: http://www.drugbank.ca/drugs/DB00573 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
|||
| Primary | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
|||
| Primary | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
28.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
105.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
Disc. AE: Reaction gastrointestinal, Reaction skin... Other AEs: Dyspepsia, Nausea... AEs leading to discontinuation/dose reduction: Reaction gastrointestinal (2%) Other AEs:Reaction skin (1%) Cardiovascular disorder (NOS) (0.5%) Dyspepsia (10%) Sources: Nausea (7.7%) Constipation (7%) Vomiting (2.6%) Abdominal pain (2%) Diarrhea (1.8%) Headache (8.7%) Somnolence (8.5%) Dizziness (6.5%) Tremor (2.2%) Confusion (1.4%) Sweating increased (4.6%) Pruritus (4.2%) Rash (3.7%) Tinnitus (4.5%) Blurred vision (2.2%) Hearing decreased (1.6%) Palpitations (2.5%) Nervousness (5.7%) Asthenia (5.4%) Peripheral edema (5%) Dyspnea (2.8%) Fatigue (1.7%) Upper respiratory infection (1.5%) Nasopharyngitis (1.2%) Gastritis (<1%) Ulcer peptic with perforation (<1%) Ulcer peptic with perforation (<1%) Gastrointestinal hemorrhage (<1%) Anorexia (<1%) Flatulence (<1%) Dry mouth (<1%) Blood in stool (<1%) Alkaline phosphatase increased (<1%) LDH increased (<1%) SGOT increased (<1%) Jaundice (<1%) Cholestatic hepatitis (<1%) Buccal mucosa aphthous ulceration (<1%) Taste metallic (<1%) Pancreatitis (<1%) Atrial fibrillation (<1%) Pulmonary edema (<1%) Electrocardiogram change (<1%) Supraventricular tachycardia (<1%) Renal failure (<1%) Dysuria (<1%) Cystitis (<1%) Hematuria (<1%) Oliguria (<1%) Azotemia (<1%) Anuria (<1%) Nephritis interstitial (<1%) Nephrosis (<1%) Acute papillary necrosis (<1%) Angioedema (<1%) Purpura (<1%) Bruising (<1%) Hemorrhage (<1%) Thrombocytopenia (<1%) Hemolytic anemia (<1%) Aplastic anemia (<1%) Agranulocytosis (<1%) Pancytopenia (<1%) Depression (<1%) Disorientation (<1%) Seizures (<1%) Trigeminal neuralgia (<1%) Burning tongue (<1%) Diplopia (<1%) Optic neuritis (<1%) Exfoliative dermatitis (<1%) Toxic epidermal necrolysis (<1%) Stevens-Johnson syndrome (<1%) Alopecia (<1%) Anaphylaxis (<1%) Urticaria (<1%) Malaise (<1%) Insomnia (<1%) Tachycardia (<1%) Personality change (<1%) Lymphadenopathy (<1%) Mastodynia (<1%) Fever (<1%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cardiovascular disorder (NOS) | 0.5% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Reaction skin | 1% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nasopharyngitis | 1.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Confusion | 1.4% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Upper respiratory infection | 1.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Hearing decreased | 1.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Fatigue | 1.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Diarrhea | 1.8% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dyspepsia | 10% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Abdominal pain | 2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Reaction gastrointestinal | 2% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Blurred vision | 2.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Tremor | 2.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Palpitations | 2.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Vomiting | 2.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dyspnea | 2.8% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Rash | 3.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Pruritus | 4.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Tinnitus | 4.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Sweating increased | 4.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Peripheral edema | 5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Asthenia | 5.4% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nervousness | 5.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dizziness | 6.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Constipation | 7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nausea | 7.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Somnolence | 8.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Headache | 8.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Acute papillary necrosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Agranulocytosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Alkaline phosphatase increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Alopecia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Anaphylaxis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Angioedema | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Anorexia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Anuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Aplastic anemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Atrial fibrillation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Azotemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Blood in stool | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Bruising | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Buccal mucosa aphthous ulceration | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Burning tongue | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Cholestatic hepatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Cystitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Depression | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Diplopia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Disorientation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dry mouth | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dysuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Electrocardiogram change | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Exfoliative dermatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Fever | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Flatulence | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Gastritis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Gastrointestinal hemorrhage | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Hematuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Hemolytic anemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Hemorrhage | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Insomnia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Jaundice | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| LDH increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Lymphadenopathy | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Malaise | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Mastodynia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nephritis interstitial | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nephrosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Oliguria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Optic neuritis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Pancreatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Pancytopenia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Personality change | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Pulmonary edema | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Purpura | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Renal failure | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| SGOT increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Seizures | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Stevens-Johnson syndrome | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Supraventricular tachycardia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Tachycardia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Taste metallic | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Thrombocytopenia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Toxic epidermal necrolysis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Trigeminal neuralgia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Ulcer peptic with perforation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Ulcer peptic with perforation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Urticaria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. | 2006 Nov |
|
| Prophylaxis of migraine. | 2006 Sep |
|
| Seasonality effects on pharmaceuticals and s-triazine herbicides in wastewater effluent and surface water from the Canadian side of the upper Detroit River. | 2006 Sep |
|
| The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. | 2007 Apr 1 |
|
| Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. | 2007 Dec |
|
| A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives. | 2007 Dec 26 |
|
| Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. | 2007 Jan |
|
| Synthesis and in vitro antitumor effect of diclofenac and fenoprofen thiolated and nonthiolated polyaspartamide-drug conjugates. | 2007 Jan |
|
| A peripatetic pediatrician's journey into pediatric rheumatology: Part II. | 2007 Jun 21 |
|
| Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. | 2007 Mar |
|
| Fenoprofen and ketoprofen amides as potential antitumor agents. | 2007 Mar |
|
| Enantioseparation by CE with vancomycin as chiral selector: Improving the separation performance by dynamic coating of the capillary with poly(dimethylacrylamide). | 2007 Mar |
|
| Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction? | 2007 May |
|
| Rapid online-SPE-MS/MS method for ketoprofen determination in dermal interstitial fluid samples from rats obtained by microdialysis or open-flow microperfusion. | 2007 May 1 |
|
| Stereoselective disposition of fenoprofen in plasma and synovial fluid of patients with rheumatoid arthritis. | 2007 May 5 |
|
| Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant. | 2007 Nov |
|
| Removal of selected pharmaceuticals by chlorination, coagulation-sedimentation and powdered activated carbon treatment. | 2008 |
|
| Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis. | 2008 |
|
| Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. | 2008 |
|
| Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. | 2008 |
|
| Efficient, selective, and green: catalyst tuning for highly enantioselective reactions of ethylene. | 2008 Apr 17 |
|
| A combination of statistical and analytical evaluation methods as a new optimization strategy for the quantification of pharmaceutical residues in sewage effluent. | 2008 Apr 21 |
|
| Chiral separation of fluvastatin enantiomers by capillary electrophoresis. | 2008 Aug |
|
| Species differences in inhibition potential of nonsteroidal anti-inflammatory drugs against estradiol 3beta-glucuronidation between rats, dogs, and humans. | 2008 Jul |
|
| Interactions between APP secretases and inflammatory mediators. | 2008 Jun 18 |
|
| The effect of piroxicam on the formation of postoperative, intraabdominal adhesion in rats. | 2008 Oct |
|
| Robust open tubular layer of S-ketoprofen imprinted polymer for chiral LC separation. | 2008 Sep |
|
| Evaluation of pharmaceuticals and personal care products as water-soluble molecular markers of sewage. | 2008 Sep 1 |
|
| Chemoenzymatic and microbial dynamic kinetic resolutions. | 2009 Apr |
|
| Using subcritical/supercritical fluid chromatography to separate acidic, basic, and neutral compounds over an ionic liquid-functionalized stationary phase. | 2009 Apr 17 |
|
| Combined use of chiral ionic liquid and CD for MEKC: Part II. Determination of binding constants. | 2009 Aug |
|
| The novel phosphoramidate derivatives of NSAID 3-hydroxypropylamides: synthesis, cytostatic and antiviral activity evaluations. | 2009 Jan |
|
| Synthesis of dehydroabietic acid-modified chitosan and its drug release behavior. | 2009 Jan 5 |
|
| Antioxidant activity of NSAID hydroxamic acids. | 2009 Jun |
|
| Synthesis and biological evaluation of O-methyl and O-ethyl NSAID hydroxamic acids. | 2009 Oct |
|
| Ibuprofen-arginine generates nitric oxide and has enhanced anti-inflammatory effects. | 2009 Oct |
|
| Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. | 2009 Sep |
|
| The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. | 2010 |
|
| PPARs in Irradiation-Induced Gastrointestinal Toxicity. | 2010 |
|
| Rapid simultaneous determination of four non-steroidal anti-inflammatory drugs by means of derivative nonlinear variable-angle synchronous fluorescence spectrometry. | 2010 Aug |
|
| Enantiomeric separation of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs by HPLC with hydroxypropyl-beta-cyclodextrin as chiral mobile phase additive. | 2010 Aug |
|
| Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. | 2010 Feb 18 |
|
| Occurrence and risk assessment of acidic pharmaceuticals in the Yellow River, Hai River and Liao River of north China. | 2010 Jul 15 |
|
| A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. | 2010 Jul 8 |
|
| Cyclooxygenase Inhibitors, Aspirin and Ibuprofen, Inhibit MHC-restricted Antigen Presentation in Dendritic Cells. | 2010 Jun |
|
| Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting. | 2010 Mar |
|
| Use of a robust dehydrogenase from an archael hyperthermophile in asymmetric catalysis-dynamic reductive kinetic resolution entry into (S)-profens. | 2010 May 5 |
|
| Primaquine-NSAID twin drugs: Synthesis, radical scavenging, antioxidant and Fe2+ chelating activity. | 2010 Sep |
|
| Electrokinetic supercharging focusing in capillary zone electrophoresis of weakly ionizable analytes in environmental and biological samples. | 2010 Sep |
|
| Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping. | 2010 Sep 16 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Fenoprofen calcium
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY | |||
|
1269505
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY | |||
|
267171
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY | RxNorm | ||
|
m5281
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY | Merck Index | ||
|
DBSALT001038
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY | |||
|
64747
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY | |||
|
0X2CW1QABJ
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY | |||
|
0X2CW1QABJ
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY | |||
|
CHEMBL1297
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY | |||
|
C61761
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY | |||
|
SUB02120MIG
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY | |||
|
100000092319
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY | |||
|
5005
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY | |||
|
53746-45-5
Created by
admin on Fri Dec 15 16:26:41 GMT 2023 , Edited by admin on Fri Dec 15 16:26:41 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
